ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 116,400 shares, an increase of 19.1% from the December 31st total of 97,700 shares. Based on an average daily volume of 290,200 shares, the short-interest ratio is currently 0.4 days.
Hedge Funds Weigh In On ProPhase Labs
Large investors have recently added to or reduced their stakes in the company. Sheets Smith Wealth Management purchased a new stake in ProPhase Labs in the fourth quarter valued at about $158,000. Geode Capital Management LLC boosted its stake in shares of ProPhase Labs by 9.2% in the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after buying an additional 13,590 shares during the last quarter. Finally, HighTower Advisors LLC grew its stake in shares of ProPhase Labs by 18.3% during the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after purchasing an additional 27,673 shares during the period. 9.45% of the stock is currently owned by institutional investors.
ProPhase Labs Stock Performance
Shares of NASDAQ PRPH opened at $0.26 on Monday. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs has a 12-month low of $0.26 and a 12-month high of $7.48. The stock’s fifty day simple moving average is $0.65 and its two-hundred day simple moving average is $1.73.
Analysts Set New Price Targets
Read Our Latest Research Report on ProPhase Labs
About ProPhase Labs
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Featured Articles
- Five stocks we like better than ProPhase Labs
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- How to Calculate Options Profits
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- 3 Stocks to Consider Buying in October
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.